Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

Armata AP-PA02-201

I'm Interested!

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection. ARMATA AP-PA02-201

  • Sex at Birth: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase II
  • Conditions Being Studied: Bronchiectasis

Study Purpose

The first study of AP PA02 was recently conducted in subjects with cystic fibrosis (Study AP PA02 101). This small study is completed, with a limited amount of data, so risks and side effects are not fully known. In this study, all side effects reported were mild or moderate and self-limited. The main purpose of this study is to learn how well the study drug works, how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone.

Who Can Participate

Age: 18 and older

Principal Investigator
Alex Gifford MD
Department/Division
Pulmonary and Critical Care Medicine (Medicine)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: STUDY20231258
  • StudyID: 2023-01219
  • ClinicalTrials.gov: NCT05616221
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422